Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07322159 | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07277504 | Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07256353 | Allogeneic UCB-derived CAR-T for B-ALL | not yet recruiting | Early Phase 1 | 50 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07244666 | Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07201064 | A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 12 | Guangdong ProCapZoom Biosciences Co., Ltd.INDUSTRY | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Oct 1, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07172178 | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma | not yet recruiting | Early Phase 1 | 12 | Nanjing Medical UniversityOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07117175 | A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy | not yet recruiting | Early Phase 1 | 18 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07113977 | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy | not yet recruiting | Early Phase 1 | 30 | Wei GuanOTHER | 0 | Aug 11, 2025 | clinicaltrials |
| NCT07077330 | CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms(CAR19BCMA) | not yet recruiting | Early Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07066436 | ImmunoMRI for Assessment of Tumor-associated Macrophages | not yet recruiting | Early Phase 1 | 60 | Medical University of ViennaOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05557708 | A Safety Study of 212Pb-Pentixather Radioligand Therapy | not yet recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07028918 | A Prospective Single-Arm Study（NCLDR）(NCLDR) | not yet recruiting | Early Phase 1 | 35 | Qilu Hospital of Shandong UniversityOTHER | 0 | Jun 19, 2025 | clinicaltrials |
| NCT07003178 | A Study to Evaluate the Safety and Clinical Efficacy of STR-P004 | not yet recruiting | Early Phase 1 | 30 | Starna TherapeuticsINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06979661 | Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy(PORT) | not yet recruiting | Early Phase 1 | 25 | Rutgers, The State University of New JerseyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06849401 | The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 15, 2025 | clinicaltrials |
| NCT06932861 | Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma | not yet recruiting | Early Phase 1 | 5 | Xinxin ZhangOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT06876701 | The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults | not yet recruiting | Early Phase 1 | 10 | Ruijin HospitalOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT06756295 | A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)(FAST-CR) | not yet recruiting | Early Phase 1 | 154 | Fengming KongOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06837389 | Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors | not yet recruiting | Early Phase 1 | 18 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06654206 | Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients | not yet recruiting | Early Phase 1 | 40 | University of SalamancaOTHER | 0 | Feb 19, 2025 | clinicaltrials |
| NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia. | not yet recruiting | Early Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06752473 | KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 10 | Kousai Bio Co., Ltd.OTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06735508 | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | not yet recruiting | Early Phase 1 | 40 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia(iNK-r/r AML) | not yet recruiting | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06685653 | Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | not yet recruiting | Early Phase 1 | 65 | Nanjing Tianyinshan HospitalOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT06646783 | Phase IIT Trial of SNA014 | not yet recruiting | Early Phase 1 | 28 | SmartNuclide BiopharmaINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06559644 | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia | not yet recruiting | Early Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06557096 | CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC | not yet recruiting | Early Phase 1 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06370026 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT03763396 | Azoles Targeting Recurrent High Grade Gliomas | not yet recruiting | Early Phase 1 | 30 | University Health Network, TorontoOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06298266 | To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 15 | Guangdong Second Provincial General HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06212388 | Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | not yet recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04662788 | Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04657965 | LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies | not yet recruiting | Early Phase 1 | 144 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jan 7, 2026source: clinicaltrials